Other Science

Klick Health Builds Out Global Leadership Team and Offices

Retrieved on: 
Thursday, November 10, 2022
Consulting, Marketing, Advertising, Communications, Professional Services, Biotechnology, Pharmaceutical, Health, Science, Other Science

Building on its recent news about taking the company global, Klick Health today made several senior, global leadership team announcements as it builds out regional hubs in Asia-Pacific (APAC); Europe, the Middle East, and Africa (EMEA); and Latin America (LATAM).

Key Points: 
  • Building on its recent news about taking the company global, Klick Health today made several senior, global leadership team announcements as it builds out regional hubs in Asia-Pacific (APAC); Europe, the Middle East, and Africa (EMEA); and Latin America (LATAM).
  • Michael Becker Chief Financial Officer, Klick Group
    Becker joins as Klick Group CFO with invaluable global finance leadership in the life sciences industry.
  • Follow Klick Health on LinkedIn and for more information on joining Klick, go to careers.klick.com .
  • The Klick Group of companiesKlick Health (including Klick Katalyst), Klick Media Group, Klick Applied Sciences (including Klick Labs), Klick Consulting, Klick Ventures, and Sensei Labsis an ecosystem of brilliant talent collectively working to maximize their peoples and clients full potential.

Pharmacovigilance Global Market Report 2022: Rising Cases of Adverse Drug Reactions Fueling Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022
Health, Science, Other Science, Pharmaceutical, Clinical Trials, Disulfiram-like drug, Service, ADR, Diabetes, Service provider, Clinical trial, Contract, Conditional sentence, Tufts University, Pharmacovigilance, PHV, Health professional, Time, Adverse drug reaction, Disease, Iatrogenesis, ADE, Method, Treatment, Growth, Marketing, Dietary supplement, Cancer, Neoplasm, Spontaneous

The "Pharmacovigilance Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmacovigilance Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The pharmacovigilance market is anticipated to grow at a compound annual growth rate of 13.5% for the forecasted period (2022-2030).
  • As the world's population ages, chronic diseases have increased; and more adverse drug reactions mean more pharmacovigilance.
  • The surge in cases of adverse drug reactions (ADR), the increasing occurrence of chronic diseases (Diabetes, Cancer, etc.)

OncoNano Medicine Announces Pre-Clinical Data for Dual-Activating STING agonist at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Research, Clinical Trials, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Stimulator of interferon genes, Doctor of Philosophy, Syngenic, Therapeutic index, Nucleic acid metabolism, Immunotherapy, Patient, Society, SITC, Pharmaceutical industry, MD

OncoNano Medicine, Inc. today announced the presentation of data on its pre-clinical candidate ONM-501 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, Massachusetts.

Key Points: 
  • OncoNano Medicine, Inc. today announced the presentation of data on its pre-clinical candidate ONM-501 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, Massachusetts.
  • ONM-501, OncoNanos lead therapeutic program in development, is a dual-activating STING (Stimulator of Interferon Genes) agonist advancing towards a first in human trial planned to be initiated in the first half of 2023.
  • Previously published data has demonstrated the differentiated mechanism of ONM-501 with dual burst and sustained STING activation, enhanced cytosolic delivery and tumor retention through encapsulation of an endogenous STING agonist - cGAMP with OnocoNanos proprietary STING-activating OMNI polymeric micelles.
  • The results presented here confirm many of our hypotheses regarding the potential of ONM-501 to provide a robust therapeutic index of immune activating STING activity that may be differentiated from other STING agonists.

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Retrieved on: 
Thursday, November 10, 2022
Research, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Health, Optical, Science, Oncology, Other Science

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2022 and provided clinical development and operational highlights.

Key Points: 
  • Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2022 and provided clinical development and operational highlights.
  • Aura is planning to enroll approximately 75 adult patients with early-stage CM, including patients with indeterminate lesions and small choroidal melanoma.
  • Positive interim Phase 2 data evaluating SC administration of bel-sar for the first-line treatment of patients with early-stage CM were presented at AAO 2022.
  • Aura plans to pursue development of bel-sar across its ocular oncology franchise including for the treatment of patients with choroidal metastasis.

Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer Therapies’ Clinical Development Program

Retrieved on: 
Thursday, November 10, 2022
Research, Clinical Trials, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Tumor microenvironment, Collagen, PET, Immunotherapy, Health, RPT, Neoplasm, Technology, CD8, DDR1, Therapy, Doctor of Philosophy, Cancer, Phenotype, Biomarker, Drug development, Clinical trial, Cell, Patient, Immune system, TME, Data, Phase II, Pharmaceutical industry, Medical imaging, Parthenon

This knowledge will help us design a clinical strategy to focus on those patients who will benefit the most from treatment with PRTH-101.

Key Points: 
  • This knowledge will help us design a clinical strategy to focus on those patients who will benefit the most from treatment with PRTH-101.
  • Under the terms of the agreement, ImaginAb will supply clinical doses of its investigational CD8 ImmunoPET technology to Parthenon Therapeutics for use in the clinical development of PRTH-101 at clinical trial sites across the United States.
  • ImaginAb is actively investing in the clinical and global supply chain development of CD8 ImmunoPET agent to provide simple turnkey access to its novel technology for use in clinical research and development.
  • Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME).

PerkinElmer to Present at 2022 Stifel Healthcare Conference

Retrieved on: 
Thursday, November 10, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Medical Devices, Conference, PerkinElmer, PKI, NYSE, Company, Management

PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 2022 Stifel Healthcare Conference on Wednesday, November 16, 2022 at 9:10 a.m.

Key Points: 
  • PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 2022 Stifel Healthcare Conference on Wednesday, November 16, 2022 at 9:10 a.m.
  • Max Krakowiak, senior vice president and chief financial officer at PerkinElmer, will provide an overview on the Company and its strategic priorities during a fireside chat.
  • A live audio webcast will be available on the Latest Events section of the Companys investor relations website.
  • PerkinElmer, Inc. is a global leader focused on innovating for a healthier world.

Seagen Names David R. Epstein as Chief Executive Officer and Director

Retrieved on: 
Thursday, November 10, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Director, Flagship Pioneering, Chairperson, Leadership, SRL Diagnostics, Fingolimod, U.S. Securities and Exchange Commission, RMIT School of Economics, Finance and Marketing, CMO, Interim, Amgen, Research, Risk, Denosumab, Intention, Merck, Technology, Board, Novartis, Hematology, Columbia University Graduate School of Journalism, Merck & Co., Secukinumab, Control, Gilead Sciences, Board of directors, Rutgers University College, Union, Inc., Cancer, Science, Drug development, Research and development, ADC, Patient, Heart, CEO, Security (finance), Business, Marketing, Management, Fine chemical, Pharmaceutical industry, Pembrolizumab, Pharmacy, Seagen, Imatinib, Sacubitril/valsartan

Seagen Inc. (Nasdaq: SGEN) today announced that its Board of Directors has appointed David R. Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors.

Key Points: 
  • Seagen Inc. (Nasdaq: SGEN) today announced that its Board of Directors has appointed David R. Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors.
  • In addition, Seagen announced that Roger Dansey, M.D., who has served as Seagens Chief Medical Officer (CMO) since 2018 and as Interim CEO since May 2022, has been appointed President, Research and Development.
  • Mr. Epstein said, I have long admired Seagen as a leader in the development and commercialization of transformative cancer therapies.
  • David R. Epstein has more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale.

binx health Announces Strategic Supply Agreement with Afaxys to Expand Sexual Health Test Access to Thousands of Clinics Nationally

Retrieved on: 
Thursday, November 10, 2022
Women, Other Science, Medical Supplies, FDA, General Health, Logistics, Supply Chain Management, Public Policy, Government, Consumer, Healthcare Reform, Medical Devices, Infectious Diseases, Health Technology, LGBTQ+, Transport, AIDS, University, Health, Education, State, Local, Science, CT, University, Pre-exposure prophylaxis, GPO, Gonorrhea, Health, Community, Sexually transmitted infection, HIV, Associated Press, FDA, Partnership, Risk, Binx, Organization, Technology, Diagnosis, NG, CDC, Man, Parenthood, Chlamydia, United, STD, Health equity, Patient, Public health, Health minister, Woman, STI, Infection, Group purchasing organization, Pharmaceutical industry, Birth control, Medical device

binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced a strategic agreement with Afaxys Group Services LLC to expand access to sexual health and wellness testing nationally through their Group Purchasing Organization (GPO) .

Key Points: 
  • binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced a strategic agreement with Afaxys Group Services LLC to expand access to sexual health and wellness testing nationally through their Group Purchasing Organization (GPO) .
  • Under the agreement, binx will offer its FDA-cleared, CLIA-waived point-of-care test for chlamydia (CT) and gonorrhea (NG) and its at-home digital health platform to thousands of clinics across the United States, under a preferred pricing model with joint marketing outreach among Afaxys and binx.
  • With this agreement, we will be able to help more patients receive the tests they need in a way that works best for them.
  • We applaud the important work of Afaxys and its member clinics in furthering healthcare access and are thrilled to join their GPO network, said Jeffrey Luber, Chief Executive Officer of binx health.

RootPath Announces Data on Tumor Reactivity Through Its Proprietary Platform at the Society for Immunology of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Health, Other Health, Other Science, General Health, Science, Biotechnology, TIL, Melanoma, TCR, Liver cancer, TAAS, Biology, Neoplasm, Technology, Synthetic biology, Population, Efficiency, DNA, ELISpot, PD-1, ICB, SITC, Cell, CEO, Society, Pathfinder, Blood, Immunology, Vaccine, Medical imaging

We are pleased that data continue to validate our platform, which can identify tumor reactive TCRs at unprecedented scale.

Key Points: 
  • We are pleased that data continue to validate our platform, which can identify tumor reactive TCRs at unprecedented scale.
  • Previous studies have demonstrated that PD-1 may be a biomarker for tumor reactive T-cells in peripheral blood.
  • The second presentation covers rapid discovery of personalized TCRs through a single-cell transcriptomic signature predicting tumor reactivity.
  • To enable this, RootPath uses its TCR synthesis, screening technology, and reactivity database to develop a gene signature, Interpreter, that predicts tumor reactivity from single cell sequencing data.

Castor Launches Real-World Evidence Offering to Simplify Post-Marketing Clinical Trials

Retrieved on: 
Thursday, November 10, 2022
Data Management, Biotechnology, Technology, FDA, Health, Pharmaceutical, Other Science, Research, Software, Science, Clinical Trials, Real-World Evidence, Clinical data management, Research, Patient, Collection, Compliance, CEO, M.D, RWD, Drug discovery, RWE, Pharmaceutical industry

Castor , a leading provider of decentralized and hybrid clinical trial technology solutions, today announced a new offering to simplify post-marketing clinical trials.

Key Points: 
  • Castor , a leading provider of decentralized and hybrid clinical trial technology solutions, today announced a new offering to simplify post-marketing clinical trials.
  • The offering, Castor Real-World Evidence (RWE), provides integrated technology and services to accelerate the collection of RWD for PMCT, enabling life science companies to meet regulatory and payer requirements efficiently.
  • We are committed to supporting life science companies in all aspects of their clinical trials, from early drug discovery to post-marketing studies, said Castor CPTO Andy Sadler.
  • Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research.